Analyst Ratings for U.S. Bancorp

Within the last quarter, U.S. Bancorp (NYSE:USB) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…

Within the last quarter, U.S. Bancorp (NYSE:USB) has observed the following analyst ratings:

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 1 7 3 0 0
Last 30D 0 1 0 0 0
1M Ago 0 1 1 0 0
2M Ago 0 3 2 0 0
3M Ago 1 2 0 0 0

In the last 3 months, 11 analysts have offered 12-month price targets for U.S. Bancorp. The company has an average price target of $61.64 with a high of $77.00 and a low of $51.00.

Below is a summary of how these 11 analysts rated U.S. Bancorp over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more negative analysts are on the stock

price target chart

This current average represents a 0.58% decrease from the previous average price target of $62.00.

Stay up to date on U.S. Bancorp analyst ratings.

Analyst Ratings: What Are They?

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company’s revenue streams are.

Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.

Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Affirm Earnings Came In Cold: What Do Analysts Think About The Stock Now?

Affirm Holdings Inc (NASDAQ: AFRM) topped off the earnings season for “buy now, pay later” and lending stocks with a disappointing report Wednesday — a possible indicator that the upcoming reports for other stocks in the sector may be just as sour.

AFRM

Read More

FibroGen Unveils Early Data From Prostate Cancer Candidate, Analyst Advocates Further Exploration In The Landscape

FibroGen reveals Phase 1 results for FG-3246 for metastatic castration-resistant prostate cancer. Promising efficacy metrics and plans for enhanced therapeutic strategies signal potential advancements in treatment. Learn more about this groundbreaking development."

ABBV